EUCTR2007-003492-39-ES进行中（未招募）不适用
Estudio en fase III en el que se comparan la eco cardiografía de contraste de miocardio SonoVue® y la tomografía de emisión monofotónica sincronizada con el ECG (ECG-GATEDSPECT en reposo y en prueba de esfuerzo máximo con dipiridamol a dosis bajas, para la evaluación de coronariopatías significativasen pacientes con coronariografía confirmada o posible, utilizándose como prueba de referencia la coronariografíaA phase III study to compare SonoVue® enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole stress test, in the assessment of significant coronary artery disease (CAD) in patients with suspect or known CAD using Coronary Angiography as Gold Standard - SonoVue MCE vs SPECT
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 597
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Having at least 18 years of age.
- •Having a known or suspected coronary artery disease (CAD) indicated for stress ECG-gated SPECT and coronary angiography to clarify whether they have a clinical significant coronary stenosis (=70%).
- •Having provided written Informed Consent and willing to comply with protocol requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Has any clinically unstable cardiac condition prior to SonoVue® administration such as:
- •evolving or ongoing myocardial infarction,
- •a history of acute myocardial infarction or PCI within the previous 3 months,
- •worsening of typical angina at rest within the previous 7 days,
- •significant worsening of cardiac symptoms within the previous 7 days,
- •recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of ECG, laboratory or clinical findings),
- •acute cardiac failure, class III/IV cardiac failure,
- •severe cardiac rhythm disorders (ventricular tachycardia sustained and not sustained in combination with symptoms).
- •Has any contra-indications to dipyridamole or aminophylline (e.g. hypersensitivity to xanthines) according to each agent’s package insert.
- •Has any known allergy to one or more of the ingredients of the investigational product.
- •Has a previous Coronary Artery By-pass.
- •Has any revascularization procedure or change of clinical status that may warrant a change in their status of CAD among the clinical testing under evaluation (coronary angiography, MCE or ECG-GATED SPECT).
- •Has used methylated xanthines (chocolate, caffeine – including coffee, tea, and cola drinks), phosphodiesterase inhibitor drugs such as aminophylline or dipyridamole within 24 hours prior SonoVue® enhanced echocardiography or SPECT.
- •Has not visualization of left ventricle at basal echocardiography.
- •Has received an investigational compound within 30 days before admission into this study.
- •Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations.
- •Is determined by the Investigator that the subject is clinically unsuitable for the study.
- •Is a pregnant or lactating female. Exclude the possibility of pregnancy:
- •by testing on site at the institution (serum or urine ßHCG) within 24 hours prior to the start of investigational product administration,
- •by surgical history (e.g., tubal ligation or hysterectomy),
- •post menopausal with a minimum 1 year without menses.
研究者
相似试验
进行中（未招募）
1 期
Estudio Fase III, randomizado, que compara el tratamiento estándar de primera línea docetaxel/prednisona en combinación con custirsen (OGX-011) en varones con cáncer de próstata metastásico hormonoresistente// A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer - SYNERGYEUCTR2010-021011-16-ESTeva Pharmaceutical Industries, Ltd1,022
进行中（未招募）
1 期
estudio ?Estudio fase III en el que se compara Pemetrexed, Cisplatino y radioterapia, seguido de tratamiento deconsolidación con Pemetrexed, frente a Etopósido, Cisplatino y radioterapia, seguido de tratamiento de consolidación con quimioterapia citotóxica de elección, en pacientes con cáncer de pulmón no microcítico con histología predominantemente no escamosa,irresecable, localmente avanzado, en estadio III?Protocol H3E-MC-JMIGPhase 3 Study of Pemetrexed, Cisplatin, andRadiotherapy Followed by Consolidation Pemetrexedversus Etoposide, Cisplatin, and Radiotherapy Followedby Consolidation Cytotoxic Chemotherapy of Choice inPatients with Unresectable, Locally Advanced, Stage IIINon-Small Cell Lung Cancer Other than PredominantlySquamous Cell HistologyEUCTR2008-001170-32-ESilly S.A.598
已完成
不适用
A phase III comparative study to evaluate the efficacy and safety of SJP-0125 versus brinzolamide in patients with primary open-angle glaucoma or ocular hypertensioJPRN-UMIN000028494Senju Pharmaceutical Co.,Ltd.376
已完成
不适用
A phase III comparative study to evaluate the efficacy and safety of SJP-0135 versus timolol in patients with primary open-angle glaucoma or ocular hypertensioPrimary open-angle glaucoma (broad definition) or ocular hypertensionJPRN-UMIN000026472Senju Pharmaceutical co.,ltd.408
已完成
不适用
A phase III comparative study to evaluate the efficacy and safety of SJP-0125 versus brimonidine tartrate in patients with primary open-angle glaucoma or ocular hypertensioPrimary open-angle glaucoma (broad definition) or ocular hypertensionJPRN-UMIN000028493Senju Pharmaceutical Co.,Ltd.320